Please login to the form below

Not currently logged in
Email:
Password:

T790M mutation

This page shows the latest T790M mutation news and features for those working in and with pharma, biotech and healthcare.

AZ’s soon-to-be lung cancer blockbuster Tagrisso approved in Japan

AZ’s soon-to-be lung cancer blockbuster Tagrisso approved in Japan

Dave Fredrickson, Executive Vice President, Head of the Oncology Business Unit, AstraZeneca, said: “Tagrisso is already approved in Japan for the treatment of patients with EGFR T790M mutation-positive inoperable or ... Today’s approval moves the use

Latest news

  • AZ speeds first-line lung cancer filing for Tagrisso to EMA AZ speeds first-line lung cancer filing for Tagrisso to EMA

    Tagrisso has been growing fast in its approved indication as a second-line therapy for EGFR-positive NSCLC after patients develop resistance (the T790M mutation) and progress on Iressa or Tarceva, ... Conversely, others argue that this denies patients

  • AZ gets rapid approval in China for Tagrisso AZ gets rapid approval in China for Tagrisso

    Tagrisso (osimertinib) - a third-generation EGFR inhibitor - has been approved by the China Food and Drug Administration (CFDA) as a second-line treatment for EGFR T790M mutation-positive metastatic non-small ... Last December, AZ reported head-to-head

  • AZ's Tagrisso beats chemotherapy in lung cancer trial AZ's Tagrisso beats chemotherapy in lung cancer trial

    to standard therapy in patients with T790M mutation-positive, locally-advanced or metastatic NSCLC. ... Tagrisso is a third-generation EGFR inhibitor and was the first drug to be approved to treat patients with metastatic EGFR T790M mutation-positive

  • Reformed Cancer Drugs Fund backs its first drug - AZ’s Tagrisso Reformed Cancer Drugs Fund backs its first drug - AZ’s Tagrisso

    In the meantime, the recently-relaunched CDF will give around 300 patients across England and Wales access to Tagrisso as a second-line treatment for advanced metastatic EGFR T790M mutation-positive ... This is the system working as it should.”.

  • FDA panel says no to quick approval of Clovis' rociletinib FDA panel says no to quick approval of Clovis' rociletinib

    Rociletinib is under review for the treatment of non-small cell lung cancer (NSCLC) patients whose tumours are epidermal growth factor receptor (EGFR) positive and carry the T790M resistance mutation. ... T790M is the most commonly encountered and

More from news
Approximately 1 fully matching, plus 15 partially matching documents found.

Latest Intelligence

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    resistance mechanisms for first and second generation inhibitors is the emergence of T790m, which basically switches on that same pathway again. ... Another development is AZD9291 – a drug which addresses the T790M mutation, which is a key resistance

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics